All In Biotech

Drug Trial Radar · NCT06703177

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase IB/II Study of Safety, Tolerability and Efficacy of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

876

Planned (sponsor's estimate)

Start

Feb 18, 2025

Primary completion

Jan 1, 2026

Study completion Jul 1, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-1826Drug

    SHR-1826

  • SHR-4642Drug

    SHR-4642

  • SHR-9839Drug

    SHR-9839

  • SHR-8068Drug

    SHR-8068

  • Bevacizumab InjectionDrug

    Bevacizumab Injection

  • Fluorouracil InjectionDrug

    Fluorouracil Injection

  • Calcium Folinate InjectionDrug

    Calcium Folinate Injection

  • Adebrelimab InjectionDrug

    Adebrelimab Injection

  • Capecitabine tabletsDrug

    Capecitabine tablets, oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2D (Phase 1)Time frame: Screening up to study completion, an average of 1 year.
  2. AE (Phase 1)Time frame: Screening up to study completion, an average of 1 year.
  3. Objective response rate (ORR) (Phase 2)Time frame: Screening up to study completion, an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen university cancer center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.